Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Five Groups Urge Action to Secure Medical Supplies amid Iran War
Five organizations, including the Japan Federation of Cancer Patient Groups, submitted a petition on April 1 to the Ministry of Health, Labor and Welfare (MHLW), calling for measures to ensure the stable supply of medical materials amid rising tensions in…
To read the full story
ORGANIZATION
- JPMA to Set Up Task Force on US MFN Policy, First Meeting Seen This Month
April 21, 2026
- PhRMA Warns Japan Launches Could Erode Global Revenues amid US MFN Policy
April 20, 2026
- JPMA Exec Frets over Material Cost Surge amid Middle East Crisis
April 17, 2026
- JPMA Reshaping Organization to Boost Agility as It Shifts to Legal Entity
April 16, 2026
- JPMA to Launch Nitrosamine Risk Project for APIs in FY2026
April 15, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…